Medgenics (MDGN) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Medgenics Reports Third Quarter 2016 Financial Results
November 3, 2016 8:01 AM EDTPHILADELPHIA, PA -- (Marketwired) -- 11/03/16 -- Medgenics, Inc. (NASDAQ: MDGN)
Presented Data Confirming Prevalence of Genetic Mutations in Pediatric ADHD at the 63rd Annual American Academy of Child and Adolescent Psychiatry (AACAP) Meeting Began Trading on the NASDAQ Global MarketsMedgenics, Inc. (NASDAQ: MDGN) (the Company) today announced third quarter 2016 financial results and provided a business update.
"We are pleased with the Company's accomplishments during the first nine months of 2016," stated Mike Cola, CEO of Medgenics. "The... More
